Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384407855> ?p ?o ?g. }
- W4384407855 endingPage "1031" @default.
- W4384407855 startingPage "1015" @default.
- W4384407855 abstract "Objectives Metastasis is still one of the main obstacles in the treatment of breast cancer. This study aimed to develop the disulfiram (DSF) and doxorubicin (DOX) co-loaded nanoparticles (DSF-DOX NPs) with enzyme/pH dual stimuli-responsive characteristics to inhibit breast cancer metastasis.Methods DSF-DOX NPs were prepared using the amphiphilic poly (ε-caprolactone)-b-poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) (PCL-b-PGlu-g-mPEG) copolymer by a classical dialysis method. The in vitro release tests, in vitro cytotoxicity assay, and anti-metastasis studies were conducted to evaluate pH/enzyme sensitivity and therapeutic effect of the DSF-DOX NPs.Results The specific pH and enzyme stimuli-responsive of DSF-DOX NPs could be attributed to the transformation of secondary structure and the degradation of amide bonds in the PGlu segment, respectively. This accelerated drug release significantly increased the cytotoxicity to 4T1 cells. Compared with the control group, the DSF-DOX NPs showed a strong inhibition of in vitro metastasis with a wound healing rate of 36.50% and a migration rate of 18.39%. Impressively, in vivo anti-metastasis results indicated that the metastasis of 4T1 cells was almost completely suppressed by DSF-DOX NPs.Conclusion DSF-DOX NPs with controllable tumor-site delivery of DOX and DSF was a prospectively potential strategy for metastatic breast cancer treatment." @default.
- W4384407855 created "2023-07-16" @default.
- W4384407855 creator A5000128145 @default.
- W4384407855 creator A5005488393 @default.
- W4384407855 creator A5009374812 @default.
- W4384407855 creator A5017376277 @default.
- W4384407855 creator A5025212717 @default.
- W4384407855 creator A5025674242 @default.
- W4384407855 creator A5038388552 @default.
- W4384407855 creator A5050080798 @default.
- W4384407855 creator A5064105778 @default.
- W4384407855 creator A5066300258 @default.
- W4384407855 creator A5067320455 @default.
- W4384407855 creator A5090291392 @default.
- W4384407855 date "2023-07-03" @default.
- W4384407855 modified "2023-10-17" @default.
- W4384407855 title "Enzyme/pH dual stimuli-responsive nanoplatform co-deliver disulfiram and doxorubicin for effective treatment of breast cancer lung metastasis" @default.
- W4384407855 cites W1186835836 @default.
- W4384407855 cites W1965636780 @default.
- W4384407855 cites W2002182083 @default.
- W4384407855 cites W2006250811 @default.
- W4384407855 cites W2013262011 @default.
- W4384407855 cites W2040658202 @default.
- W4384407855 cites W2041191822 @default.
- W4384407855 cites W2045115557 @default.
- W4384407855 cites W2054057500 @default.
- W4384407855 cites W2078694420 @default.
- W4384407855 cites W2082833890 @default.
- W4384407855 cites W2100662195 @default.
- W4384407855 cites W2113274437 @default.
- W4384407855 cites W2140088548 @default.
- W4384407855 cites W2141690509 @default.
- W4384407855 cites W2151230162 @default.
- W4384407855 cites W2161397941 @default.
- W4384407855 cites W2163482611 @default.
- W4384407855 cites W2166549342 @default.
- W4384407855 cites W2204030946 @default.
- W4384407855 cites W2568972635 @default.
- W4384407855 cites W2747732435 @default.
- W4384407855 cites W2772508026 @default.
- W4384407855 cites W2796211793 @default.
- W4384407855 cites W2804156096 @default.
- W4384407855 cites W2900128797 @default.
- W4384407855 cites W2903659409 @default.
- W4384407855 cites W2938054231 @default.
- W4384407855 cites W2944968176 @default.
- W4384407855 cites W2963932652 @default.
- W4384407855 cites W2967901922 @default.
- W4384407855 cites W2982396938 @default.
- W4384407855 cites W2997311366 @default.
- W4384407855 cites W3037179091 @default.
- W4384407855 cites W3048944217 @default.
- W4384407855 cites W3087167818 @default.
- W4384407855 cites W3096705092 @default.
- W4384407855 cites W3099524685 @default.
- W4384407855 cites W3101915942 @default.
- W4384407855 cites W3103150521 @default.
- W4384407855 cites W3104406294 @default.
- W4384407855 cites W3130994100 @default.
- W4384407855 cites W3134254717 @default.
- W4384407855 cites W3135875197 @default.
- W4384407855 cites W3145563628 @default.
- W4384407855 cites W3160360879 @default.
- W4384407855 cites W3198085713 @default.
- W4384407855 cites W4200024543 @default.
- W4384407855 cites W4200310335 @default.
- W4384407855 cites W4200376172 @default.
- W4384407855 cites W4206527368 @default.
- W4384407855 cites W4207043059 @default.
- W4384407855 cites W4210945757 @default.
- W4384407855 cites W4213385871 @default.
- W4384407855 cites W4221066375 @default.
- W4384407855 cites W4225880115 @default.
- W4384407855 cites W4281865876 @default.
- W4384407855 cites W4283331795 @default.
- W4384407855 cites W4292395993 @default.
- W4384407855 cites W4292474509 @default.
- W4384407855 cites W4296534905 @default.
- W4384407855 cites W4309781227 @default.
- W4384407855 cites W4316037791 @default.
- W4384407855 cites W4317492689 @default.
- W4384407855 cites W4322155348 @default.
- W4384407855 cites W4323536387 @default.
- W4384407855 cites W4360993878 @default.
- W4384407855 doi "https://doi.org/10.1080/17425247.2023.2237888" @default.
- W4384407855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37452715" @default.
- W4384407855 hasPublicationYear "2023" @default.
- W4384407855 type Work @default.
- W4384407855 citedByCount "0" @default.
- W4384407855 crossrefType "journal-article" @default.
- W4384407855 hasAuthorship W4384407855A5000128145 @default.
- W4384407855 hasAuthorship W4384407855A5005488393 @default.
- W4384407855 hasAuthorship W4384407855A5009374812 @default.
- W4384407855 hasAuthorship W4384407855A5017376277 @default.
- W4384407855 hasAuthorship W4384407855A5025212717 @default.
- W4384407855 hasAuthorship W4384407855A5025674242 @default.
- W4384407855 hasAuthorship W4384407855A5038388552 @default.
- W4384407855 hasAuthorship W4384407855A5050080798 @default.